Compound ID | 2988
NVC-422 (Aganocide®, Auriclosene)
Synonym(s): N,N-dichloro-2,2-dimethyltaurine
Class: Antivirulence agent
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Active against Staphylococcus aureus, Streptococcus pyogenes, vancomycin-resistant Enterococcus faecium, Staphylococcus epidermidis, Escherichia coli, Enterobacter aerogenes, Acinetobacter baumannii, Klebsiella pneumoniae, Proteus mirabilis, Haemophilus influenzae, Pseudomonas aeruginosa, and Serratia marcescens |
| Description: | Synthetic compound; active and well tolerated when administered as topical gel treatment for impetigo in children |
| Institute where first reported: | NovaBay Pharmaceuticals, Inc. |
| Year first mentioned: | 2011 |
| Highest developmental phase: | Phase 2 (NCT01367314; NCT00781339; NCT01532336; NCT01877694; NCT01243125) |
| Development status: | Unknown |
| Reason Dropped: | No results posted after clinical trial completion |
| External links: | |
| Guide to Pharmacology: | auriclosene |
| Main Source: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160610/ |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us.
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.